3 Positives From This Week’s GlaxoSmithKline plc Results

GlaxoSmithKline plc (LON:GSK) disappointed investors this week, but Roland Head believes that the stock remains a long-term buy.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

gskGlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) stock fell when the firm published its results on Wednesday, leaving the pharma giant’s share price down by nearly 5% when markets closed.

Although the headline figures weren’t great — core operating profit fell by 14% during the first half of 2014 — I think that yesterday’s reaction was overdone, and believe that yesterday’s results contained several positives for shareholders.

1. Out with the old…

The biggest decline in sales came from the Established Products segment of Glaxo’s portfolio, where sales on a constant currency basis fell by 24% during the second quarter. However, that doesn’t mean these products are without value, and Glaxo is planning to realise £1bn by selling some of them later this year.

At the other end of the lifecycle, the firm reported strong performance from several new respiratory products and from its new HIV product, Tivicay, which already has an 11% market share, and is performing ahead of recently-launched competitor products.

2. Dividend up

Glaxo announced a 6% increase in the second quarter dividend yesterday, but the firm’s usually-strong cash generation has been hit hard by the strength of the pound against other currencies, meaning that free cash flow is down by 70% on the first half of 2013.

As a result, Glaxo has taken the decision to stop buying back shares for the remainder of 2014, which seems a good decision to me: unless a firm’s stock is very cheap, I’d rather free cash flow was used to fund dividends than buybacks, which only benefit sellers (through a higher share price).

3. Vaccine growth

Another bright spot was vaccine sales, which rose by 4%, generating a 32% increase in core operating profits, which rose to £289m.

Although some of this increase was due to favourable timings of sales, and stockpile movements, it’s worth noting that the Vaccines division generated Glaxo’s highest operating margin, at 37%.

Vaccine sales currently account for 20% of profits, but this year’s complex deal with Novartis is designed to strengthen Glaxo’s vaccine business, which the firm believes can generate ‘mid-single digit sales growth’ over the medium to long term.

Is Glaxo a buy?

Overall, I continue to rate Glaxo as a buy.

The firm’s exceptional 27% operating margin means that its forecast P/E of 14.5 looks cheap, in my view, and although currency headwinds are a concern, they should be manageable for Glaxo.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head owns shares in GlaxoSmithKline. The Motley Fool recommends GlaxoSmithKline.

More on Investing Articles

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »